{"component": "definition", "props": {"groups": [{"size": 6, "snippet": "shall have the meaning set forth in Section 2.1(a).", "snippet_links": [], "samples": [{"hash": "fXsbe5K9uap", "uri": "/contracts/fXsbe5K9uap#target-list", "label": "Research Collaboration and License Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 18.0, "published": true}, {"hash": "fRj6OQjvTCN", "uri": "/contracts/fRj6OQjvTCN#target-list", "label": "Research Collaboration and License Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 18.0, "published": true}, {"hash": "98hRHcZ0aUI", "uri": "/contracts/98hRHcZ0aUI#target-list", "label": "Research Collaboration and License Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 18.0, "published": true}], "hash": "76ee071a1f1f0127bb711c699cc5a9c5", "id": 1}, {"size": 3, "snippet": "and \u201cTarget List Rep\u201d shall have the meanings set forth in Section 3.2.2.", "snippet_links": [{"key": "the-meanings", "type": "definition", "offset": [33, 45]}], "samples": [{"hash": "gaeiYV2nMNw", "uri": "/contracts/gaeiYV2nMNw#target-list", "label": "Collaboration and License Agreement (CureVac B.V.)", "score": 31.5790554415, "published": true}, {"hash": "3cXtnAIXdkw", "uri": "/contracts/3cXtnAIXdkw#target-list", "label": "Collaboration and License Agreement (CureVac B.V.)", "score": 31.559890486, "published": true}, {"hash": "bNoDBtDZX43", "uri": "/contracts/bNoDBtDZX43#target-list", "label": "Collaboration and License Agreement (CureVac B.V.)", "score": 31.4722792608, "published": true}], "hash": "68cc6162da12a6b85e4a38880114ec95", "id": 2}, {"size": 2, "snippet": "is defined in Section 4.5.", "snippet_links": [{"key": "section-45", "type": "clause", "offset": [14, 25]}], "samples": [{"hash": "fKY0eMypDbY", "uri": "/contracts/fKY0eMypDbY#target-list", "label": "License and Collaboration Agreement (Signal Genetics, Inc.)", "score": 28.0088980151, "published": true}, {"hash": "gWmXIC8lnDF", "uri": "/contracts/gWmXIC8lnDF#target-list", "label": "License and Collaboration Agreement (Signal Genetics, Inc.)", "score": 27.9185489391, "published": true}], "hash": "dddeefc2620e0033efeb1c5d7f584f67", "id": 3}, {"size": 2, "snippet": "means the list of Targets attached hereto as Schedule 1.119, as such list may be updated or modified by the JRC pursuant to Section 3.5.", "snippet_links": [{"key": "the-jrc", "type": "clause", "offset": [104, 111]}, {"key": "section-35", "type": "clause", "offset": [124, 135]}], "samples": [{"hash": "eOHNf7VQ7h", "uri": "/contracts/eOHNf7VQ7h#target-list", "label": "Discovery and Development Collaboration and License Agreement (Agios Pharmaceuticals Inc)", "score": 24.537303217, "published": true}, {"hash": "l05FZWq4Fem", "uri": "/contracts/l05FZWq4Fem#target-list", "label": "Discovery and Development Collaboration and License Agreement (Agios Pharmaceuticals Inc)", "score": 24.4387405886, "published": true}], "hash": "e04c1a8bc077ab5223132ab30d9065ed", "id": 4}, {"size": 2, "snippet": "means the list of Targets on the Rolling Target List and the Immunized Target List, but excluding Excluded Targets.", "snippet_links": [{"key": "but-excluding", "type": "clause", "offset": [84, 97]}, {"key": "excluded-targets", "type": "clause", "offset": [98, 114]}], "samples": [{"hash": "erDewQFMoZP", "uri": "/contracts/erDewQFMoZP#target-list", "label": "Discovery and Preclinical Development Agreement (Regeneron Pharmaceuticals Inc)", "score": 21.4161533196, "published": true}, {"hash": "1AVsRaRF3ok", "uri": "/contracts/1AVsRaRF3ok#target-list", "label": "Discovery and Preclinical Development Agreement (Regeneron Pharmaceuticals Inc)", "score": 21.1314168378, "published": true}], "hash": "8f9bfebb42b59d6ed4d9ab3deeed78b9", "id": 5}, {"size": 1, "snippet": "means the list of customers identified by Quinnova as their customers, which is agreed to by Oculus. 1.18 \u201cTarget Professionals\u201d shall mean a podiatrist who is legally authorized to prescribe the Products. 1.19 \"Term\" shall have the meaning provided in Section 8.1 hereof. 2 1.20 \"Territory\" shall mean the continental United States, its territories and Canada. 1.21 \"Third Party\" shall mean any entity other than Quinnova or Oculus or an Affiliate of either party. 1.22 \"TRx\" shall mean total prescriptions of a Product generated by Target Professionals. 2.", "snippet_links": [{"key": "list-of-customers", "type": "clause", "offset": [10, 27]}, {"key": "agreed-to-by", "type": "clause", "offset": [80, 92]}, {"key": "target-professionals", "type": "definition", "offset": [107, 127]}, {"key": "legally-authorized", "type": "clause", "offset": [160, 178]}, {"key": "the-products", "type": "clause", "offset": [192, 204]}, {"key": "section-81", "type": "clause", "offset": [253, 264]}, {"key": "continental-united-states", "type": "definition", "offset": [307, 332]}, {"key": "third-party", "type": "clause", "offset": [368, 379]}, {"key": "affiliate-of", "type": "definition", "offset": [439, 451]}, {"key": "either-party", "type": "definition", "offset": [452, 464]}], "samples": [{"hash": "7ONFVNKFtlB", "uri": "/contracts/7ONFVNKFtlB#target-list", "label": "Exclusive Co Promotion Agreement", "score": 30.340862423, "published": true}], "hash": "d54c26fdd6ff3dad4eab5f7f318152fa", "id": 6}, {"size": 1, "snippet": "has the meaning set forth in Section 3.3.1 (Target List).", "snippet_links": [{"key": "section-331", "type": "clause", "offset": [29, 42]}], "samples": [{"hash": "55LM8rldXcC", "uri": "/contracts/55LM8rldXcC#target-list", "label": "Collaboration and License Agreement (Wave Life Sciences Ltd.)", "score": 34.2210814511, "published": true}], "hash": "06d1223df3a01666d15b468d0589c8a4", "id": 7}, {"size": 1, "snippet": "means a (*) Sublicense Fees will accrue upon the earlier of (i) the delivery of the Licensed Software to the Customer or (ii) the reproduction, deployment or use of the Licensed Software by the Customer and shall be payable quarterly as set forth in Section 6.4 of this Agreement.", "snippet_links": [{"key": "sublicense-fees", "type": "clause", "offset": [12, 27]}, {"key": "delivery-of-the-licensed-software", "type": "clause", "offset": [68, 101]}, {"key": "use-of-the-licensed-software", "type": "clause", "offset": [158, 186]}, {"key": "by-the-customer", "type": "clause", "offset": [187, 202]}, {"key": "section-64", "type": "clause", "offset": [250, 261]}, {"key": "this-agreement", "type": "clause", "offset": [265, 279]}], "samples": [{"hash": "bmOy3tVVvRz", "uri": "/contracts/bmOy3tVVvRz#target-list", "label": "Value Added Industry Remarketer Agreement (Lawson Software Inc)", "score": 18.0, "published": true}], "hash": "a62a828bd10ae1d100f4f11ff259f829", "id": 8}, {"size": 1, "snippet": "has the meaning set forth in Section 2.2.1. of this Agreement.", "snippet_links": [{"key": "this-agreement", "type": "clause", "offset": [47, 61]}], "samples": [{"hash": "4GMSGqs5jbX", "uri": "/contracts/4GMSGqs5jbX#target-list", "label": "Co Promotion Agreement (Millennium Pharmaceuticals Inc)", "score": 21.0, "published": true}], "hash": "d9aa52087638539a77801e6cc4836ae0", "id": 9}, {"size": 1, "snippet": "means a written list of Distributor's preferred Customers or active prospects, which Distributor shall provide to Siebel no later than March 31, 2000, provided, however, that Distributor may discuss such initial Target List with Siebel and make necessary modifications to the initial Target List, and shall present such modifications at one time as a final Target List within three (3) months after the Effective Date. It is understood that unless it is determined that there is a conflict under Siebel's lead registration process, the parties contemplate that Customers on the Target List will be Distributor registered leads under such process. The parties agree to meet within thirty (30) days after the Effective Date to discuss and resolve to the parties' mutual satisfaction issues concerning lead registration, rules of engagement and other similar matters. Sublicense Fees will accrue upon the earlier of (i) the delivery of the Licensed Software to the Customer or (ii) the reproduction, deployment or use of the Licensed Software by the Customer and shall be payable quarterly as set forth in Section 6.4 of this Agreement.", "snippet_links": [{"key": "written-list", "type": "clause", "offset": [8, 20]}, {"key": "of-distributor", "type": "clause", "offset": [21, 35]}, {"key": "preferred-customers", "type": "definition", "offset": [38, 57]}, {"key": "active-prospects", "type": "definition", "offset": [61, 77]}, {"key": "initial-target", "type": "definition", "offset": [204, 218]}, {"key": "modifications-to-the", "type": "clause", "offset": [255, 275]}, {"key": "after-the-effective-date", "type": "clause", "offset": [393, 417]}, {"key": "lead-registration-process", "type": "definition", "offset": [505, 530]}, {"key": "the-target", "type": "clause", "offset": [574, 584]}, {"key": "agree-to", "type": "clause", "offset": [659, 667]}, {"key": "within-thirty", "type": "clause", "offset": [673, 686]}, {"key": "days-after", "type": "definition", "offset": [692, 702]}, {"key": "to-discuss", "type": "definition", "offset": [722, 732]}, {"key": "rules-of-engagement", "type": "definition", "offset": [818, 837]}, {"key": "sublicense-fees", "type": "clause", "offset": [865, 880]}, {"key": "delivery-of-the-licensed-software", "type": "clause", "offset": [921, 954]}, {"key": "use-of-the-licensed-software", "type": "clause", "offset": [1011, 1039]}, {"key": "by-the-customer", "type": "clause", "offset": [1040, 1055]}, {"key": "section-64", "type": "clause", "offset": [1103, 1114]}, {"key": "this-agreement", "type": "clause", "offset": [1118, 1132]}], "samples": [{"hash": "eyqdBKbgSvP", "uri": "/contracts/eyqdBKbgSvP#target-list", "label": "Value Added Industry Remarketer Agreement (Lawson Software Inc)", "score": 18.0, "published": true}], "hash": "e0edccebbda5ad80c480364def284415", "id": 10}], "next_curs": "ClgSUmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjQLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIUdGFyZ2V0LWxpc3QjMDAwMDAwMGEMogECZW4YACAA", "definition": {"title": "Target List", "size": 23, "snippet": "shall have the meaning set forth in Section 2.1(a).", "id": "target-list", "examples": ["In each circumstance where BMS notifies CytomX of its desire to designate a Target as the subject of a Substitute Target or Additional Target, CytomX shall provide the target Reviewer with an updated Excluded <strong>Target List</strong> prior to BMS proposing such new Target to the Target Reviewer.", "For the avoidance of doubt, the Escrow Agent shall not notify Acuitas if a potential Reserved Target has been rejected from the Reserved <strong>Target List</strong> under this Section 4.2. All costs and expenses incurred through the Escrow Agent will be borne by Acuitas.", "The Reserved <strong>Target List</strong> existing as of the Effective Date shall be provided by FivePrime to GSK upon the execution of this Agreement in accordance with Section 3.4.1(d)(i)(2) below.", "If, as of the date of CureVac\u2019s Target Notice for a Target, such Target is not listed on the Restricted <strong>Target List</strong>, then such Target will become a Reserved Target and will be added to the Reserved <strong>Target List</strong> subject to the Concurrent Reserved List Limits set forth in subsection (d) below.", "CureVac will select the Targets that will be the subject of the Works to be performed as part of a Program from the Reserved <strong>Target List</strong>.", "After the Effective Date, FivePrime shall update the Reserved <strong>Target List</strong> and Reserved Target Identity List deposited with *** promptly after FivePrime makes any substitution to the Reserved <strong>Target List</strong>.", "FivePrime shall maintain a current Third Party <strong>Target List</strong> and shall update GSK within *** days of making any changes to the Third Party <strong>Target List</strong>.", "Upon the Parties&#x27; mutual election, or at the close of this sixty (60) day period, Abandoned Targets will be removed from the Research Program and the Selected <strong>Target List</strong> and shall cease to be Selected Targets.", "If a proposed Target is not [***] due to the provisions of this Section 2.3.2(c), such Target will not count against the Substitution Cap (if applicable) and the Vertex Target on the Vertex <strong>Target List</strong> that was to be replaced by such Target shall remain on the Vertex <strong>Target List</strong> (if applicable).", "Within two (2) days following the Gatekeeper&#x27;s receipt of the <strong>Target List</strong>, the Gatekeeper shall notify Novartis in writing (a &quot;Target Response Notice&quot;) which, if any, of the Targets identified on such <strong>Target List</strong> are on the Blocked <strong>Target List</strong> most recently delivered by Alnylam to the Gatekeeper."], "related": [["dq-list", "DQ List", "DQ List"], ["target-2", "TARGET 2", "TARGET 2"], ["soft-target", "Soft Target", "Soft Target"], ["target", "Target", "Target"], ["kpi-target", "KPI Target", "KPI Target"]], "related_snippets": [], "updated": "2025-07-06T21:58:36+00:00"}, "json": true, "cursor": ""}}